Barrett's Oesophagus (BO) is a precancerous condition, associated with chronic gastro-oesophageal reflux, resulting in a change of normal squamous epithelium of the lower oesophagus to columnar epithelium. In non-dysplastic BO, the cancer conversion rate is 0.9%/year with increasing cancer risk of 9.1%/year with low-grade dysplasia (LGD) and 25.6% risk with high-grade dysplasia (HGD) over a 3 year period.[@b1]

Within Northern Ireland, endoscopic therapy for early neoplastic changes has offered patients a less invasive treatment option with curative intent in comparison to the conventional surgical intervention. These include radiofrequency ablation (RFA) of dysplastic BO and endoscopic mucosal resection (EMR) for nodular BO as per NICE recommendations.[@b2]

All cases are carefully selected and discussed through the regional upper GI cancer multidisciplinary meeting prior to onward referral to an advanced endoscopist competent in performing these procedures.

To date, a total of 282 EMR's have been successfully performed on visible oesophageal lesions and a total of 238 RFA on dysplastic BO with curative intent.

These procedures are generally well tolerated with minimal recovery time and same day discharge. They are performed under conscious sedation and have much lower morbidity and mortality in comparison to an oesophagectomy.

The future reduction in oesophageal cancer risk due to the fact BO can be eradicated highlights the importance of this therapeutic endoscopic intervention for the future.
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